No results for ‘’
Panacea Biotec Ltd
₹397.65
(2.32%)
Tue, 15 Sept 2026, 10:02 am
Health Technology
Pharmaceuticals: Major
24.5KPanacea Biotec Price to Sales Ratio (P/S)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 41.13 | 19.02 | 17.68 | 0 | 19.26 | 7.95 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32.18 | 0 | 0 | 0.84 | 0 | 0 | 0 |
| Price to book ratio | 14.15 | 5.09 | 3.22 | 0.64 | 2.10 | 1.72 | 0.57 | 1.22 | 1.13 | 1.89 | 1.32 | 2.77 | 5.30 | 3.46 | 3.37 | 0 | 1.04 | 0.79 | 0.88 | 3.23 |
| Price to sales ratio | 4.21 | 3.30 | 2.82 | 0.53 | 1.75 | 1.01 | 0.72 | 1.33 | 1.17 | 1.27 | 0.91 | 1.85 | 2.79 | 2.68 | 1.25 | 1.76 | 1.38 | 1.45 | 1.34 | 5.47 |
| Price to cash flow ratio | 14.85 | 17.25 | 38.79 | 0 | 54.85 | 28.14 | 2.95 | 0 | 0 | 52.42 | 34.22 | 29.65 | 191.82 | 30.54 | 0 | 100.62 | 0 | 0 | 58.76 | 0 |
| Enterprise value | 2515Cr | 2810Cr | 2615Cr | 1051Cr | 2235Cr | 1967Cr | 1367Cr | 1706Cr | 1625Cr | 1919Cr | 1650Cr | 1974Cr | 2549Cr | 1834Cr | 1320Cr | 1767Cr | 351Cr | 441Cr | 580Cr | 2546Cr |
| Enterprise value to EBITDA ratio | 20.62 | 12.02 | 11.80 | 4.62 | 17.60 | 8.60 | 0 | 0 | 0 | 32.10 | 15.53 | 31.60 | 29.62 | 0 | 24.10 | 22.55 | 0 | 0 | 25.59 | 0 |
| Debt to equity ratio | 2.39 | 0.40 | 0.57 | 1.14 | 1 | 1.33 | 1 | 1.57 | 2.07 | 2.34 | 2.43 | 2.79 | 3.05 | 1.85 | 3.73 | 0 | 0.04 | 0.02 | 0.02 | 0.03 |
| Return on equity % | 25.89 | 37.77 | 21.77 | -9.98 | 12.39 | 21.41 | -26.99 | -31.23 | -19.70 | -21.66 | -3.98 | -9.75 | -21.55 | 12.43 | -68.40 | 0 | 332.84 | -3.93 | -0.14 | -1 |
Panacea Biotec Ltd Price to Sales Ratio
The Panacea Biotec Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Panacea Biotec Ltd's valuation, profitability, and overall financial performance. Tracking the Panacea Biotec Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Panacea Biotec Ltd (NSE: PANACEABIO, BSE: 531349) is currently trading at ₹397.65, with a market capitalization of ₹2438.09Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Panacea Biotec Ltd Price to Sales Ratio is essential for fundamental analysis.
Panacea Biotec Ltd Price to Sales Ratio Current Value
The current Panacea Biotec Ltd Price to Sales Ratio stands at 5.47.
The latest Panacea Biotec Ltd Price to Sales Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Panacea Biotec Ltd Price to Sales Ratio Historical Trend
The Panacea Biotec Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 5.47
- 2023: 1.34
- 2022: 1.45
- 2021: 1.38
- 2020: 1.76
The recent rise in Panacea Biotec Ltd Price to Sales Ratio suggests strengthening valuation trends and improving market sentiment.
What Panacea Biotec Ltd Price to Sales Ratio Indicates for Investors
The Panacea Biotec Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Panacea Biotec Ltd Price to Sales Ratio Analysis Summary
The Panacea Biotec Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Panacea Biotec Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Panacea Biotec Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.